Why Evommune, Inc.’s (EVMN) Stock Is Up 10.61%
As of Friday, August 21, Evommune, Inc.’s EVMN share price has surged by 10.61%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Commentary & Analysis
Why Evommune, Inc.’s (EVMN) Stock Is Up 5.34%
As of Friday, August 07, Evommune, Inc.’s EVMN share price has surged by 5.34%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Evommune, Inc.’s (EVMN) Stock Is Up 5.35%
As of Tuesday, August 04, Evommune, Inc.’s EVMN share price has surged by 5.35%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Evommune, Inc.’s (EVMN) Stock Is Down 7.37%
As of Thursday, July 23, Evommune, Inc.’s EVMN share price has dipped by 7.37%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Evommune, Inc.’s (EVMN) Stock Is Down 6.47%
As of Monday, July 20, Evommune, Inc.’s EVMN share price has dipped by 6.47%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | EVMN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $508.8 | $292.6 | 37% |
|
| Shares Out (Mil) | 36.1 | 54.4 | 40% |
|
| Institutional Ownership | 96.3% | 93.2% | 69% |
|
| Float (Mil) | 19.9 | 40.2 | 29% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 406 | 544 | 54% |
|
| Price Change (52-week) |
na | 59.7% | na |
|
| Growth | EVMN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 10 | 10 | |
| Current EPS | ($0.814) | ($3.379) | ($3.364) | |
| Month Ago EPS | ($0.746) | ($2.793) | ($3.241) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 3 | 3 | 2 | |
| Three Months Ago EPS | ($0.688) | ($2.778) | ($3.331) | |
| Year/Year Chg | (8.7%) | (69.9%) | (67.6%) | |
| Financials | EVMN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $10 | $37 | 9% |
|
| Net Income (TTM) (Mil) | ($95) | ($43) | 11% |
|
| EPS (TTM) | ($4.148) | ($1.400) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($74) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $2 | 40% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $4 | 26% |
|
| Enterprise Value (Q1) (Mil) | na | $164 | na |
|
| Valuation | EVMN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.83 | 2.83 | 46% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | EVMN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 64.2% | 96% |
|
| Net Margin | (946.7%) | (75.9%) | 0% |
|
| ROA | (47.6%) | (47.5%) | 12% |
|
| ROE | (178.0%) | (55.0%) | 5% |
|
| Liabilities to Assets | 8.1% | 29.6% | 5% |
|
| F-Score | 2 | 3 | 7% |
|
Evommune, Inc. did not pass any screens on 8/21/2026.
